Candidate genes for type 1 diabetes modulate pancreatic islet inflammation and β-cell apoptosis

Diabetes, Obesity and Metabolism

Volumn 15, Issue S3, 2013, Pages 71-81

  Santin, I ^a   Eizirik, D L ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Apoptosis; Candidate genes; Cytokines; Inflammation; Pancreatic cells; Type 1 diabetes

Indexed keywords

INTERFERON;

ANTIVIRAL ACTIVITY; APOPTOSIS; CELL LOSS; EPIGENETICS; GENE; GENE EXPRESSION; GENETIC POLYMORPHISM; HUMAN; IMMUNE SYSTEM; INFLAMMATION; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PATHOGENESIS; PHENOTYPE; REVIEW; VIRUS INFECTION;

APOPTOSIS; CANDIDATE GENES; CYTOKINES; INFLAMMATION; PANCREATIC Β-CELLS; TYPE 1 DIABETES;

APOPTOSIS; AUTOIMMUNITY; DIABETES MELLITUS, TYPE 1; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION STUDIES; HUMANS; INFLAMMATION; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS;

EID: 84883533518     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12162     Document Type: Review

References (97)

1. Todd JA. Etiology of type 1 diabetes. Immunity 2010; 32: 457-467.
2. Pociot F, Akolkar B, Concannon P et al. Genetics of type 1 diabetes: what's next? Diabetes 2010; 59: 1561-1571.
3. Wandstrat A, Wakeland E. The genetics of complex autoimmune diseases: non-MHC susceptibility genes. Nat Immunol 2001; 2: 802-809.
4. Smyth DJ, Plagnol V, Walker NM et al. Shared and distinct genetic variants in type 1 diabetes and celiac disease. N Engl J Med 2008; 359: 2767-2777.
5. Wang H, Jin Y, Reddy MV et al. Genetically dependent ERBB3 expression modulates antigen presenting cell function and type 1 diabetes risk. PLoS One 2010; 5: e11789.
6. Long SA, Cerosaletti K, Wan JY et al. An autoimmune-associated variant in PTPN2 reveals an impairment of IL-2R signaling in CD4(+) T cells. Genes Immun 2011; 12: 116-125.
7. Eizirik DL, Sammeth M, Bouckenooghe T et al. The human pancreatic islet transcriptome: expression of candidate genes for type 1 diabetes and the impact of pro-inflammatory cytokines. PLoS Genet 2012; 8: e1002552.
8. Eizirik DL, Colli ML, Ortis F. The role of inflammation in insulitis and β-cell loss in type 1 diabetes. Nat Rev Endocrinol 2009; 5: 219-226.
9. Lander ES. Initial impact of the sequencing of the human genome. Nature 2011; 470: 187-197.
10. Klein C, Lohmann K, Ziegler A. The promise and limitations of genome-wide association studies. JAMA 2012; 308: 1867-1868.
11. Li C, Han J, Shang D et al. Identifying disease related sub-pathways for analysis of genome-wide association studies. Gene 2012; 503: 101-109.
12. Concannon P, Rich SS, Nepom GT. Genetics of type 1A diabetes. N Engl J Med 2009; 360: 1646-1654.
13. Moore F, Colli ML, Cnop M et al. PTPN2, a candidate gene for type 1 diabetes, modulates interferon-γ-induced pancreatic β-cell apoptosis. Diabetes 2009; 58: 1283-1291.
14. Colli ML, Moore F, Gurzov EN, Ortis F, Eizirik DL. MDA5 and PTPN2, two candidate genes for type 1 diabetes, modify pancreatic β-cell responses to the viral by-product double-stranded RNA. Hum Mol Genet 2010; 19: 135-146.
15. Santin I, Moore F, Colli ML et al. PTPN2, a candidate gene for type 1 diabetes, modulates pancreatic β-cell apoptosis via regulation of the BH3-only protein Bim. Diabetes 2011; 60: 3279-3288.
16. Bergholdt R, Brorsson C, Palleja A et al. Identification of novel type 1 diabetes candidate genes by integrating genome-wide association data, protein-protein interactions, and human pancreatic islet gene expression. Diabetes 2012; 61: 954-962.
17. Santin I, Moore F, Grieco FA, Marchetti P, Brancolini C, Eizirik DL. USP18 is a key regulator of the interferon-driven gene network modulating pancreatic β-cell inflammation and apoptosis. Cell Death Dis 2012; 3: e419.
18. Yang Y, Chang BH, Chan L. Sustained expression of the transcription factor GLIS3 is required for normal β-cell function in adults. EMBO Mol Med 2013; 5: 92-104.
19. Nogueira TC, Paula FV, Villate O et al. GLIS3, a susceptibility gene for type 1 and 2 diabetes mellitus, modulates pancreatic beta cell apoptosis via regulation of a splice variant of the BH3-only protein Bim. PLoS Genet 2013; 9: e1003532.
20. Noble JA, Valdes AM. Genetics of the HLA region in the prediction of type 1 diabetes. Curr Diab Rep 2011; 11: 533-542.
21. Todd JA, Bell JI, McDevitt HO. HLA-DQβ gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature 1987; 329: 599-604.
22. Qu HQ, Bradfield JP, Belisle A, Grant SF, Hakonarson H, Polychronakos C. The type I diabetes association of the IL2RA locus. Genes Immun 2009; 10: S42-S48.
23. Yuan X, Malek TR. Cellular and molecular determinants for the development of natural and induced regulatory T cells. Hum Immunol 2012; 73: 773-782.
24. Skog O, Korsgren O, Frisk G. Modulation of innate immunity in human pancreatic islets infected with enterovirus in vitro. J Med Virol 2011; 83: 658-664.
25. Downes K, Pekalski M, Angus KL et al. Reduced expression of IFIH1 is protective for type 1 diabetes. PLoS One 2010; 5: e12646.
26. Zhernakova A, Stahl EA, Trynka G et al. Meta-analysis of genome-wide association studies in celiac disease and rheumatoid arthritis identifies fourteen non-HLA shared loci. PLoS Genet 2011; 7: e1002004.
27. Ramanan VK, Shen L, Moore JH, Saykin AJ. Pathway analysis of genomic data: concepts, methods, and prospects for future development. Trends Genet 2012; 28: 323-332.
28. Eleftherohorinou H, Wright V, Hoggart C et al. Pathway analysis of GWAS provides new insights into genetic susceptibility to 3 inflammatory diseases. PLoS One 2009; 4: e8068.
29. Helfand RF, Gary HE Jr, Freeman CY, Anderson LJ, Pallansch MA. Serologic evidence of an association between enteroviruses and the onset of type 1 diabetes mellitus. Pittsburgh Diabetes Research Group. J Infect Dis 1995; 172: 1206-1211.
30. Lonnrot M, Salminen K, Knip M et al. Enterovirus RNA in serum is a risk factor for β-cell autoimmunity and clinical type 1 diabetes: a prospective study. Childhood Diabetes in Finland (DiMe) Study Group. J Med Virol 2000; 61: 214-220.
31. Dotta F, Censini S, van Halteren AG et al. Coxsackie B4 virus infection of β-cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proc Natl Acad Sci USA 2007; 104: 5115-5120.
32. Yeung WC, Rawlinson WD, Craig ME. Enterovirus infection and type 1 diabetes mellitus: systematic review and meta-analysis of observational molecular studies. BMJ 2011; 342: d35.
33. Richardson SJ, Leete P, Bone AJ, Foulis AK, Morgan NG. Expression of the enteroviral capsid protein VP1 in the islet cells of patients with type 1 diabetes is associated with induction of protein kinase R and downregulation of Mcl-1. Diabetologia 2013; 56: 185-193.
34. Randall RE, Goodbourn S. Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol 2008; 89: 1-47.
35. Huang X, Yuang J, Goddard A et al. Interferon expression in the pancreases of patients with type I diabetes. Diabetes 1995; 44: 658-664.
36. Reynier F, Pachot A, Paye M et al. Specific gene expression signature associated with development of autoimmune type-I diabetes using whole-blood microarray analysis. Genes Immun 2010; 11: 269-278.
37. Lind K, Huhn MH, Flodstrom-Tullberg M. Immunology in the clinic review series; focus on type 1 diabetes and viruses: the innate immune response to enteroviruses and its possible role in regulating type 1 diabetes. Clin Exp Immunol 2012; 168: 30-38.
38. Li Q, Xu B, Michie SA, Rubins KH, Schreriber RD, McDevitt HO. Interferon-α initiates type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci USA 2008; 105: 12439-12444.
39. Stewart TA. Neutralizing interferon α as a therapeutic approach to autoimmune diseases. Cytokine Growth Factor Rev 2003; 14: 139-154.
40. Foxman EF, Iwasaki A. Genome-virome interactions: examining the role of common viral infections in complex disease. Nat Rev Microbiol 2011; 9: 254-264.
41. Heinig M, Petretto E, Wallace C et al. A trans-acting locus regulates an anti-viral expression network and type 1 diabetes risk. Nature 2010; 467: 460-464.
42. Rasschaert J, Ladriere L, Urbain M et al. Toll-like receptor 3 and STAT-1 contribute to double-stranded RNA+interferon-γ-induced apoptosis in primary pancreatic β-cells. J Biol Chem 2005; 280: 33984-33991.
43. Hultcrantz M, Huhn MH, Wolf M et al. Interferons induce an antiviral state in human pancreatic islet cells. Virology 2007; 367: 92-101.
44. Dogusan Z, Garcia M, Flamez D et al. Double-stranded RNA induces pancreatic β-cell apoptosis by activation of the toll-like receptor 3 and interferon regulatory factor 3 pathways. Diabetes 2008; 57: 1236-1245.
45. Garcia M, Dogusan Z, Moore F et al. Regulation and function of the cytosolic viral RNA sensor RIG-I in pancreatic β-cells. Biochim Biophys Acta 2009; 1793: 1768-1775.
46. Yu L, Wang L, Chen S. Endogenous toll-like receptor ligands and their biological significance. J Cell Mol Med 2010; 14: 2592-2603.
47. Barrat FJ, Meeker T, Gregorio J et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med 2005; 202: 1131-1139.
48. Quintana FJ, Rotem A, Carmi P, Cohen IR. Vaccination with empty plasmid DNA or CpG oligonucleotide inhibits diabetes in nonobese diabetic mice: modulation of spontaneous 60-kDa heat shock protein autoimmunity. J Immunol 2000; 165: 6148-6155.
49. Zhang Y, Lee AS, Shameli A et al. TLR9 blockade inhibits activation of diabetogenic CD8+ T cells and delays autoimmune diabetes. J Immunol 2010; 184: 5645-5653.
50. Devaraj S, Tobias P, Jialal I. Knockout of toll-like receptor-4 attenuates the pro-inflammatory state of diabetes. Cytokine 2011; 55: 441-445.
51. Devaraj S, Dasu MR, Park SH, Jialal I. Increased levels of ligands of Toll-like receptors 2 and 4 in type 1 diabetes. Diabetologia 2009; 52: 1665-1668.
52. Devaraj S, Dasu MR, Rockwood J, Winter W, Griffen SC, Jialal I. Increased toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients with type 1 diabetes: further evidence of a proinflammatory state. J Clin Endocrinol Metab 2008; 93: 578-583.
53. Ylipaasto P, Smura T, Gopalacharyulu P et al. Enterovirus-induced gene expression profile is critical for human pancreatic islet destruction. Diabetologia 2012; 55: 3273-3283.
54. Pichlmair A, Kandasamy K, Alvisi G et al. Viral immune modulators perturb the human molecular network by common and unique strategies. Nature 2012; 487: 486-490.
55. Takeuchi O, Akira S. MDA5/RIG-I and virus recognition. Curr Opin Immunol 2008; 20: 17-22.
56. Nejentsev S, Walker N, Riches D, Egholm M, Todd JA. Rare variants of IFIH1, a gene implicated in antiviral responses, protect against type 1 diabetes. Science 2009; 324: 387-389.
57. Winkler C, Lauber C, Adler K et al. An interferon-induced helicase (IFIH1) gene polymorphism associates with different rates of progression from autoimmunity to type 1 diabetes. Diabetes 2011; 60: 685-690.
58. Velazquez L, Fellous M, Stark GR, Pellegrini S. A protein tyrosine kinase in the interferon α/β signaling pathway. Cell 1992; 70: 313-322.
59. Wallace C, Smyth DJ, Maisuria-Armer M, Walker NM, Todd JA, Clayton DG. The imprinted DLK1-MEG3 gene region on chromosome 14q32.2 alters susceptibility to type 1 diabetes. Nat Genet 2010; 42: 68-71.
60. Tao JH, Zou YF, Feng XL et al. Meta-analysis of TYK2 gene polymorphisms association with susceptibility to autoimmune and inflammatory diseases. Mol Biol Rep 2011; 38: 4663-4672.
61. Shaw MH, Boyartchuk V, Wong S et al. A natural mutation in the Tyk2 pseudokinase domain underlies altered susceptibility of B10.Q/J mice to infection and autoimmunity. Proc Natl Acad Sci USA 2003; 100: 11594-11599.
62. Karaghiosoff M, Neubauer H, Lassnig C et al. Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity 2000; 13: 549-560.
63. Liang YL, Wu H, Shen X et al. Association of STAT4 rs7574865 polymorphism with autoimmune diseases: a meta-analysis. Mol Biol Rep 2012; 39: 8873-8882.
64. Cooper JT, Stroka DM, Brostjan C, Palmetshofer A, Bach FH, Ferran C. A20 blocks endothelial cell activation through a NF-κB-dependent mechanism. J Biol Chem 1996; 271: 18068-18073.
65. Cooper JD, Smyth DJ, Smiles AM et al. Meta-analysis of genome-wide association study data identifies additional type 1 diabetes risk loci. Nat Genet 2008; 40: 1399-1401.
66. Musone SL, Taylor KE, Nititham J et al. Sequencing of TNFAIP3 and association of variants with multiple autoimmune diseases. Genes Immun 2011; 12: 176-182.
67. Fung EY, Smyth DJ, Howson JM et al. Analysis of 17 autoimmune disease-associated variants in type 1 diabetes identifies 6q23/TNFAIP3 as a susceptibility locus. Genes Immun 2009; 10: 188-191.
68. Elsby LM, Orozco G, Denton J, Worthington J, Ray DW, Donn RP. Functional evaluation of TNFAIP3 (A20) in rheumatoid arthritis. Clin Exp Rheumatol 2010; 28: 708-714.
69. Ortis F, Pirot P, Naamane N et al. Induction of nuclear factor-κB and its downstream genes by TNF-α and IL-1β has a pro-apoptotic role in pancreatic β-cells. Diabetologia 2008; 51: 1213-1225.
70. Hayashi K, Altman A. Protein kinase C θ (PKCθ): a key player in T cell life and death. Pharmacol Res 2007; 55: 537-544.
71. Kim JK, Fillmore JJ, Sunshine MJ et al. PKC-θ knockout mice are protected from fat-induced insulin resistance. J Clin Invest 2004; 114: 823-827.
72. Haasch D, Berg C, Clampit JE et al. PKCθ is a key player in the development of insulin resistance. Biochem Biophys Res Commun 2006; 343: 361-368.
73. Mobley JL. Is rheumatoid arthritis a consequence of natural selection for enhanced tuberculosis resistance? Med Hypotheses 2004; 62: 839-843.
74. Schurr E, Gros P. A common genetic fingerprint in leprosy and Crohn's disease? N Engl J Med 2009; 361: 2666-2668.
75. Bassukas ID, Gaitanis G, Hundeiker M. Leprosy and the natural selection for psoriasis. Med Hypotheses 2012; 78: 183-190.
76. Barrett JC, Clayton DG, Concannon P et al. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet 2009; 41: 703-707.
77. Dupuis J, Langenberg C, Prokopenko I et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet 2010; 42: 105-116.
78. Rakyan VK, Beyan H, Down TA et al. Identification of type 1 diabetes-associated DNA methylation variable positions that precede disease diagnosis. PLoS Genet 2011; 7: e1002300.
79. Senee V, Chelala C, Duchatelet S et al. Mutations in GLIS3 are responsible for a rare syndrome with neonatal diabetes mellitus and congenital hypothyroidism. Nat Genet 2006; 38: 682-687.
80. Dang MN, Buzzetti R, Pozzilli P. Epigenetics in autoimmune diseases with focus on type 1 diabetes. Diabetes Metab Res Rev 2013; 29: 8-18.
81. Volkmar M, Dedeurwaerder S, Cunha DA et al. DNA methylation profiling identifies epigenetic dysregulation in pancreatic islets from type 2 diabetic patients. EMBO J 2012; 31: 1405-1426.
82. Campbell-Thompson M, Wasserfall C, Kaddis J et al. Network for pancreatic organ donors with diabetes (nPOD): developing a tissue biobank for type 1 diabetes. Diabetes Metab Res Rev 2012; 28: 608-617.
83. Miao F, Smith DD, Zhang L, Min A, Feng W, Natarajan R. Lymphocytes from patients with type 1 diabetes display a distinct profile of chromatin histone H3 lysine 9 dimethylation: an epigenetic study in diabetes. Diabetes 2008; 57: 3189-3198.
84. Gurzov EN, Ortis F, Cunha DA et al. Signaling by IL-1β+IFN-γ and ER stress converge on DP5/Hrk activation: a novel mechanism for pancreatic β-cell apoptosis. Cell Death Differ 2009; 16: 1539-1550.
85. Todd JA, Walker NM, Cooper JD et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet 2007; 39: 857-864.
86. Fernandez-Valverde SL, Taft RJ, Mattick JS. MicroRNAs in β-cell biology, insulin resistance, diabetes and its complications. Diabetes 2011; 60: 1825-1831.
87. Eizirik DL, Grieco FA. On the immense variety and complexity of circumstances conditioning pancreatic β-cell apoptosis in type 1 diabetes. Diabetes 2012; 61: 1661-1663.
88. Roggli E, Gattesco S, Caille D et al. Changes in microRNA expression contribute to pancreatic β-cell dysfunction in prediabetic NOD mice. Diabetes 2012; 61: 1742-1751.
89. Sebastiani G, Grieco FA, Spagnuolo I, Galleri L, Cataldo D, Dotta F. Increased expression of microRNA miR-326 in type 1 diabetic patients with ongoing islet autoimmunity. Diabetes Metab Res Rev 2011; 27: 862-866.
90. de Jong VM, Zaldumbide A, van der Slik AR, Persengiev SP, Roep BO, Koeleman BP. Post-transcriptional control of candidate risk genes for type 1 diabetes by rare genetic variants. Genes Immun 2013; 14: 58-61.
91. Bang-Berthelsen CH, Pedersen L, Floyel T, Hagedorn PH, Gylvin T, Pociot F. Independent component and pathway-based analysis of miRNA-regulated gene expression in a model of type 1 diabetes. BMC Genomics 2011; 12: 97.
92. Ortis F, Naamane N, Flamez D et al. Cytokines interleukin-1β and tumor necrosis factor-α regulate different transcriptional and alternative splicing networks in primary β-cells. Diabetes 2010; 59: 358-374.
93. Wenzlau JM, Juhl K, Yu L et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci USA 2007; 104: 17040-17045.
94. Greenbaum CJ, Schatz DA, Haller MJ, Sanda S. Through the fog: recent clinical trials to preserve β-cell function in type 1 diabetes. Diabetes 2012; 61: 1323-1330.
95. Dendrou CA, Bell JI, Fugger L. Weighing in on autoimmune disease: big data tip the scale. Nat Med 2013; 19: 138-139.
96. Anderson CA, Boucher G, Lees CW et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 2011; 43: 246-252.
97. Aulchenko YS, Struchalin MV, Belonogova NM et al. Predicting human height by Victorian and genomic methods. Eur J Hum Genet 2009; 17: 1070-1075.